New combo drug study for advanced prostate cancer
NCT ID NCT02123758
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 25 times
Summary
This study looked at how two drugs, JNJ-56021927 and abiraterone acetate, interact in men with advanced prostate cancer that no longer responds to hormone therapy. The goal was to check safety and find the right doses. Fifty-seven men took part, and the results help doctors understand how to combine these treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Los Angeles, California, United States
-
Study site
San Francisco, California, United States
-
Study site
Houston, Texas, United States
-
Study site
Vancouver, British Columbia, Canada
-
Study site
Montreal, Quebec, Canada
-
Study site
Rotterdam, Netherlands
-
Study site
Sutton, United Kingdom
Conditions
Explore the condition pages connected to this study.